Drug repurposing is most useful when AI helps connect a real disease mechanism to a real medicine that already has manufacturing, dosing, and safety history behind it. That sounds simple, but the evidence now spans molecular networks, transcriptomics, screening assays, clinical notes, claims data, adverse-event reports, and new trial results, which makes manual synthesis slow and inconsistent.
The strongest current systems do not treat repurposing as a magic black box. They combine knowledge graphs, graph neural networks, multimodal evidence, electronic health record data, phenotyping, real-world evidence, and early ADMET or toxicology filters so candidate lists become more testable and less noisy.
This update reflects the field as of March 21, 2026 and leans mainly on FDA and NCATS material plus recent PubMed-indexed studies. Inference: the biggest near-term gains are better evidence ranking, better subgroup selection, and faster validation of existing drugs, not fully autonomous drug discovery.
1. AI-Driven Target Identification
AI is making repurposing more credible when it starts with disease biology instead of browsing huge drug libraries for loose correlations. The best target-identification systems now look across connected genes, proteins, pathways, and disease modules to surface where an already approved or clinically characterized drug might plausibly intervene.
Recent PubMed-indexed work on a foundation model for clinician-centered drug repurposing and a separate network-medicine study in amyotrophic lateral sclerosis both point in the same direction: stronger repurposing starts by aligning drug candidates with disease-specific biological structure rather than relying on one isolated target or one similarity score. Inference: the most useful AI systems are becoming better at narrowing large mechanistic search spaces into smaller shortlists that can actually be reviewed by translational teams.
2. Multi-Omics Integration
Repurposing gets stronger when transcriptomic, proteomic, genomic, and disease-state signals are combined rather than interpreted in isolation. Multi-omics integration matters because many repurposing misses come from over-weighting one layer of biology while ignoring compensatory pathways or context-specific disease states.
DeepDRA and the ALS network-medicine study illustrate the same practical shift: models increasingly combine multiple omics layers to recover disease modules, candidate mechanisms, and repurposable compounds that would be harder to see from one assay family alone. Inference: multi-omics AI is most valuable when it reduces false confidence in simplistic one-target stories and highlights whether a drug still looks plausible after several biological views are aligned.
3. Predictive Modeling of Drug-Target Interactions
AI-based drug-target interaction modeling is useful in repurposing because it can rapidly test whether a known drug deserves attention against a different target than the one it was originally developed for. This is especially valuable when teams need to screen approved-drug libraries against a disease-relevant protein or pathway before committing to more expensive wet-lab work.
A 2024 PubMed-indexed study used graph neural networks plus docking and biological validation to identify repurposable JAK2 inhibitors from FDA-approved drugs, while ceSAR showed how transcriptional connectivity and docking can be combined to speed ranking in broader discovery and repurposing workflows. Inference: predictive interaction models are strongest when they connect statistical ranking to structural or experimental follow-up rather than stopping at a single in silico score.
4. Natural Language Processing for Literature Mining
Repurposing research depends heavily on scattered papers, case reports, mechanistic studies, patents, and trial descriptions, so natural language processing is becoming a core evidence-ingestion layer. Good literature-mining systems help teams find candidate drug-disease links, mechanistic rationale, prior failures, and safety caveats much faster than manual review alone.
The CTEPH repurposing study is a strong example of how modern pipelines use NLP, embedding methods, in vitro follow-up, and real-world evidence together instead of treating text mining as a standalone step. Inference: the most useful literature-mining systems are not only pulling terms out of papers, they are helping teams connect textual evidence to experimental and clinical validation workflows.
5. Knowledge Graphs and Reasoning Engines
Knowledge graphs matter in repurposing because drug discovery is fundamentally a relational problem. Drugs connect to targets, targets to pathways, pathways to diseases, diseases to phenotypes, and all of that sits inside a changing evidence landscape that is easier to reason over when the relationships stay explicit.
The OREGANO knowledge graph project shows how graph-based biomedical representation supports computational repurposing, while the baricitinib case remains a widely cited illustration of AI-guided prioritization leading to a drug that later showed real clinical value in a new indication. Inference: graph reasoning is most persuasive when it helps teams trace why a candidate rose in the ranking, not only that it did.
6. High-Throughput Virtual Screening
High-throughput virtual screening is one of the clearest operational wins in repurposing because approved or clinically tested compounds can be ranked far faster than they can be bench-tested. The main goal is not to claim that docking alone finds the answer. It is to reduce an impossibly large candidate space into a manageable set of experiments.
NCATS continues to support this layer through its OpenData Portal and Pharmaceutical Collection resources, and ceSAR shows how connectivity signatures and docking can be paired for faster, more selective ranking. Inference: the best screening workflows combine broad approved-drug coverage with transparent prioritization logic so experimental follow-up starts from a more realistic queue.
7. Automated Hypothesis Generation
Automated hypothesis generation is becoming more useful when it is grounded in existing drug libraries, known mechanisms, and disease-specific evidence rather than open-ended brainstorming. In repurposing, the best hypothesis engines propose testable next steps, supporting citations, and clear failure points instead of vague lists of "interesting compounds."
NCATS's New Therapeutic Uses program and its broader drug-repurposing work reflect the same operational principle seen in current AI papers: useful repurposing ideas emerge when prior pharmacology, disease biology, and practical development constraints are fused into one decision layer. Inference: strong hypothesis generation is less about creativity in the abstract and more about surfacing the next experiment or retrospective test worth paying for.
8. Mechanistic Insight into Drug Actions
Repurposing is much easier to defend when AI can explain why a drug might work in a new disease context. Mechanistic insight matters because many candidates look interesting statistically but fall apart once teams ask whether the pathway logic, cell-state evidence, or network context actually supports the new indication.
ceSAR is important here because it connects transcriptional signature similarity to structural filtering, while the baricitinib story shows how computational prioritization became more convincing once a mechanistic rationale and later clinical efficacy aligned. Inference: mechanism-aware repurposing does not eliminate uncertainty, but it improves the odds that the candidates entering animal studies or trials are scientifically defensible.
9. Real-World Evidence Extraction
Real-world evidence is becoming one of the most important repurposing layers because it lets researchers test whether a drug already being used in practice appears to change outcomes in plausible patient cohorts. The key is design rigor: observational data can generate or strengthen hypotheses, but only if bias, confounding, and cohort definition are handled seriously.
FDA's real-world evidence program and recent target-trial emulation work in Alzheimer's disease both reinforce the same message: AI can help turn messy healthcare data into useful repurposing signals, but the result only matters if the study design is principled. Inference: the strongest near-term use of EHR and claims data is not replacing trials, but prioritizing which repurposing candidates deserve the next prospective step.
10. Adverse Event Analysis as Clues
Safety data is not only about rejecting candidates. In some settings, pharmacovigilance data can also reveal unexpected beneficial patterns, tolerability profiles, or off-target activity that helps refine repurposing hypotheses. The limitation is equally important: an adverse-event signal is never the same thing as causal proof.
FDA's FAERS program and the openFDA drug-event API make it easier to analyze post-marketing safety patterns at scale, which is valuable for repurposing teams trying to understand whether a candidate's real-world safety profile fits the new indication. Inference: adverse-event mining is strongest as a clue-generating and risk-filtering layer, not as a standalone basis for selecting a new therapy.
11. Phenotypic Screening Analysis
Phenotypic screening remains one of the most grounded repurposing routes because it asks whether an existing drug changes a disease-relevant cell or organism state, even when the exact target is not fully known yet. That makes it especially useful for complex diseases where pathway logic alone does not tell the whole story.
A 2025 3D high-throughput ovarian-cancer repurposing screen and a 2024 review on repurposing plus phenotypic screening for ultra-rare disorders both show why this approach keeps returning: disease-relevant phenotypes can surface candidates that target-first methods miss. Inference: phenotypic screening becomes even stronger when AI helps score images, trajectories, or multi-readout assays instead of relying on one crude endpoint.
12. Drug Combination Synergy Prediction
Many repurposed agents will be more useful in combination than alone, but the number of possible pairs explodes too quickly for manual testing. AI helps by narrowing which combinations deserve attention first and by learning when synergy looks plausible from network structure, mechanism, or prior response data.
Recent PubMed-indexed work including SynDRep and GNNSynergy shows how graph-based models are being used to predict anti-cancer drug synergy and partner selection in more structured ways. Inference: the most valuable role for AI here is not proclaiming a final regimen, but compressing a massive combination search into a smaller bench-testing queue with clearer rationale.
13. Network Pharmacology Approaches
Network pharmacology is especially important in repurposing because existing drugs often act on multiple targets and disease biology is rarely linear. AI can help identify when a candidate fits a disease module, compensatory pathway, or polypharmacology pattern even if its original indication was very different.
The ALS multi-omics study and OREGANO both reflect the field's broader move toward connected disease modeling, where drugs are evaluated against pathway neighborhoods and disease modules rather than only one gene. Inference: network pharmacology is one reason repurposing can succeed in complex diseases where broader systems effects matter more than perfect target specificity.
14. Reinforcement Learning for Optimization
Reinforcement learning is still a cautious part of real-world repurposing, but the underlying idea of adaptive search is relevant. When lab capacity is limited, AI can help decide which experiment, dose range, disease model, or combination to test next instead of spending the same effort on a random or static queue.
NCATS Matrix projects and open-data screening programs show why adaptive prioritization matters operationally: experimental bandwidth is finite, and repurposing pipelines need principled ways to choose the next assay or combination to run. Inference: the near-term role for RL-like methods is smarter sequential experimentation and ranking, not an autonomous system that independently declares new therapies ready for use.
15. Clustering and Similarity-Based Discovery
Similarity-based repurposing is evolving beyond simple chemical resemblance. Modern systems compare drugs and diseases across phenotype, transcriptomic response, network position, and clinical association, which makes similarity more useful as a multidimensional ranking tool than as a single heuristic.
DDIT's clinical phenotypic drug-disease association work and the newer UKEDR deep-learning framework both show how similarity-based repurposing is moving toward richer, more integrated representations. Inference: clustering is most useful when it helps teams spot underappreciated neighborhoods of candidates worth validation, not when it is treated as proof by resemblance alone.
16. Federated Learning for Privacy-Preserving Insights
Federated learning matters for repurposing because the most useful clinical evidence is often distributed across health systems that cannot simply centralize raw patient records. Privacy-preserving collaboration can make subgroup discovery and outcome analysis more representative without forcing every institution to hand over sensitive data.
Recent oncology reviews on federated learning and AI-enabled real-world evidence highlight why this matters operationally: distributed clinical data networks can improve generalizability while respecting local governance constraints. Inference: for repurposing, federated approaches are most promising where they make target-trial emulation and subgroup analysis broader, more diverse, and more privacy-aware.
17. Patient Stratification and Precision Repurposing
One of the biggest advances in repurposing is the shift from asking whether a drug helps everyone to asking which patients are most likely to benefit. Precision repurposing is important because existing drugs often show mixed results in broad populations while still helping narrower, clinically coherent subgroups.
The deep subgrouping framework for precision drug repurposing via emulated trials shows how this field is moving toward subgroup-specific treatment-effect estimation rather than average-population claims. Inference: this is one of the most practical places for AI to improve repurposing because better subgrouping can rescue candidates that would otherwise look mediocre in a broad, noisy population.
18. Predictive Toxicology and Safety Profiling
Safety triage is essential in repurposing because a drug that is safe in one indication may be unacceptable in another population, dose range, duration, or comorbidity setting. AI helps by combining known labels, pharmacology, observational safety patterns, and indication context earlier in the ranking process.
FDA safety resources, FAERS, and the broader real-world repurposing literature all underscore the same point: known safety history helps, but it does not eliminate the need to reassess risk in the new use case. Inference: strong repurposing pipelines increasingly treat safety modeling as an early ranking layer alongside efficacy, not as a late-stage cleanup task.
19. Clinical Trial Candidate Selection
One of AI's most realistic roles in repurposing is deciding which candidate actually deserves a trial. Most repurposing ideas should never reach that point, and a better evidence stack helps investigators avoid spending scarce trial capacity on weakly justified compounds.
NCATS programs, FDA's interest in principled real-world evidence, and recent trial-emulation papers all support the same operational pattern: use AI to rank and pressure-test candidates before they enter formal clinical development. Inference: smarter candidate selection may be one of the highest-return repurposing uses because it improves not only speed, but also the quality of the trials that actually get launched.
20. Continuous Learning Systems
Repurposing systems are becoming more useful when they keep learning from new papers, safety reports, screening data, and clinical outcomes instead of freezing one static model or one static graph. That continuous-learning pattern matters because repurposing is a moving evidence problem, not a one-time prediction problem.
Recent reviews on real-world evidence and AI in translational oncology describe a circular workflow in which trial data, observational evidence, and updated multimodal models refine each other over time. Inference: the best repurposing platforms in 2026 are starting to look less like one-shot screens and more like governed evidence systems that re-rank candidates as the ground truth changes.
Related AI Glossary
- Real-World Evidence (RWE): Turning EHR, claims, registry, and practice data into usable evidence for repurposing and follow-up studies.
- Knowledge Graph: Representing drugs, diseases, targets, and relationships as an explicit connected network.
- Graph Neural Network (GNN): Learning directly from molecular or biomedical graph structure for ranking and prediction.
- Electronic Health Record (EHR): A key real-world data source for cohort building, trial emulation, and subgroup analysis.
- Phenotyping: Defining clinically meaningful patient states or disease patterns from messy healthcare data.
- ADMET: Early absorption, distribution, metabolism, excretion, and toxicity filters that shape whether a candidate is viable.
- Toxicology: The discipline that keeps repurposing grounded in actual safety risk rather than mechanism alone.
- Multimodal Learning: Combining omics, text, screening, and clinical evidence in one ranking workflow.
Sources and 2026 References
- NCATS: Drug Repurposing Fact Sheet
- NCATS: OpenData Portal
- NCATS: Matrix
- NCATS: Matrix Screening Projects
- NCATS: New Therapeutic Uses
- NCATS: Pharmaceutical Collection
- PubMed: A foundation model for clinician-centered drug repurposing
- PubMed: DeepDRA: Drug repurposing using multi-omics data integration with autoencoders
- PubMed: The OREGANO knowledge graph for computational drug repurposing
- PubMed: An exploration into CTEPH medications: Combining natural language processing, embedding learning, in vitro models, and real-world evidence for drug repurposing
- PubMed: Network medicine informed multiomics integration identifies drug targets and repurposable medicines for Amyotrophic Lateral Sclerosis
- PubMed: Drug Repositioning via Graph Neural Networks: Identifying Novel JAK2 Inhibitors from FDA-Approved Drugs through Molecular Docking and Biological Validation
- PubMed: Accelerating drug discovery and repurposing by combining transcriptional signature connectivity with docking
- PubMed: The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
- FDA: Real-World Evidence
- FDA Framework for Real-World Evidence Program
- PubMed: A Deep Subgrouping Framework for Precision Drug Repurposing via Emulating Clinical Trials on Real-world Patient Data
- PubMed: Critical evaluation of real-world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation
- FDA: FAERS
- openFDA: Drug Event API
- PubMed: A Novel 3D High-Throughput Phenotypic Drug Screening Pipeline to Identify Drugs with Repurposing Potential for the Treatment of Ovarian Cancer
- PubMed: Drug repurposing and phenotypic screening: innovative strategies for treating ultra-rare disorders
- PubMed: SynDRep: a synergistic partner prediction tool based on knowledge graph for drug repurposing
- PubMed: GNNSynergy: A Multi-View Graph Neural Network for Predicting Anti-Cancer Drug Synergy
- PubMed: DDIT: An Online Predictor for Multiple Clinical Phenotypic Drug-Disease Associations
- PubMed: A fused deep learning approach to transform drug repositioning
- PubMed: Advancing breast, lung and prostate cancer research with federated learning. A systematic review
- PubMed: Revolutionizing gastrointestinal cancer research with artificial intelligence: From precision patient stratification to real-world evidence
- PubMed: Drug repurposing using real-world data
Related Yenra Articles
- Molecular Design in Pharmaceuticals covers how AI helps generate and refine new molecules before repurposing becomes the better route.
- Biomarker Discovery in Healthcare adds context on the signals used to decide which patients or disease states matter most.
- Personalized Medicine broadens the same logic from repurposed drugs to individualized care decisions more generally.
- Precision Oncology and Targeted Therapies shows how subgrouping, response modeling, and repurposing intersect in a concrete clinical domain.